2020 saw a record number of new health care and life sciences FCA cases and important legal developments that will affect the enforcement landscape for years to come. Leading DOJ lawyers and whistleblower counsel address key enforcement issues, including:
- sector-specific risk areas for life sciences companies, EHR, telehealth, Medicare Part C, laboratories, and other health care providers;
- data mining and the use of data analysis in FCA enforcement;
- DOJ assessment of compliance programs;
- emerging legal developments; and
- owner/investor liability
Rachel Berk is a panelist and CRA is a proud sponsor.
For more information on this event, click here.
